These speakers are excellent, and the topic is fascinating, but I can't stop thinking about the fate of the chewing gum removed at 0.01 of the video.

Tomorrow we have a tough and prohibitive competition, as the new European Society of Cardiology guidelines will be presented at the same time. However, our session 'Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter' (Room Prague, starting at 8.15 UK time) is also, in my...

Tackling inflammation in atherosclerotic cardiovascular disease: some thoughts from today's talk at #ESCCongress. 1) Low-dose colchicine can already be added to statin therapy as well as to background therapies that might include multiple other adjunctive lipid lowering agents.

How many times have we seen this flow chart on the duration of DAPT change over the years? Let’s summarize the situation regarding class I recommendations (“must be done”) as reported in the new 2024 guidelines on chronic coronary syndromes: - High bleeding risk patient: DAPT

Coinciding with #ESCCongress 2024, EuroIntervention publishes the Percutaneous Valvular and Structural Heart Disease Interventions Core Curriculum of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). This document describes the knowledge, skills, and

It may not be the most significant change in the new guidelines for atrial fibrillation, but the shift from CHA2DS2–VASc to CHA2DS2-VA (for which they should provide the pronunciation) is interesting, also because of the rationale: 'The inclusion of gender complicates clinical

In the RESHAPE-HF2 trial, which involved patients with moderate to severe functional mitral regurgitation who remained symptomatic despite medical therapy, transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or death from

In MATTERHORN, among patients with heart failure and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral-valve surgery with respect to a composite of death, rehospitalization for heart failure, stroke, reintervention, or implantation of an

The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a significantly higher incidence of stroke or systemic embolism in the asundexian group. The findings raise questions about the adequacy of factor XIa inhibition

The SENIOR-RITA trial found that an invasive strategy involving coronary revascularization plus medical therapy did not significantly reduce the risk of cardiovascular death or nonfatal myocardial infarction compared to a conservative medical therapy approach in older patients

The DynamX bioadaptor demonstrated noninferiority to current DES at 12 months in a cohort of relatively low-risk and selected patients, primarily presenting with ACS. Following the unlock and separation phase, data from two trials now indicate a potential plateau in adverse

In patients with de novo, non-complex coronary artery disease, irrespective of vessel diameter, a strategy of DCB angioplasty with rescue stenting did not achieve non-inferiority compared with the intended DES implantation in terms of the DoCE at 2 years. This is the first of a

More on the differences between OCT and IVUS, in the randomized OPINION-ACS trial, now published. Among patients with ACS, OCT- and IVUS-guided PCI were equally safe and feasible, with comparable in-stent minimum lumen areas at 8 months. IVUS-guided PCI may facilitate larger

There is one thing that, even as a reviewer and despite having pointed it out during the process, I really haven't understood about the new ESC guidelines for chronic coronary syndromes. Using the new Risk factor-weighted clinical likelihood (RF-CL) model, one can calculate